IRIS登记系统中葡萄膜炎及免疫抑制治疗背景下白内障术后眼内炎发生率
基于美国IRIS登记系统2013年至2023年9 742 773例白内障手术的回顾性队列研究,比较葡萄膜炎及全身皮质类固醇或免疫抑制治疗背景下急性术后眼内炎发生率;结果显示合并葡萄膜炎和全身免疫抑制治疗者眼内炎发生率更高,且全身皮质类固醇较免疫抑制剂与眼内炎关联更强。
要点
- 白内障术后60天内急性眼内炎发生率:A组0.058%、B组0.468%、C组0.137%、D组0.964%。
- 葡萄膜炎诊断、全身皮质类固醇和免疫抑制药物均与白内障术后急性眼内炎风险升高相关。
- 多因素logistic回归显示全身皮质类固醇较全身免疫抑制剂与眼内炎关联更强。
核心结论
- 葡萄膜炎诊断、全身皮质类固醇和免疫抑制药物与白内障术后急性眼内炎风险升高相关。
- 多因素logistic回归分析显示全身皮质类固醇较全身免疫抑制剂与眼内炎关联更强。
研究设计与样本
- 回顾性队列研究,查询美国眼科学会IRIS登记系统2013年1月1日至2023年3月21日期间白内障手术。
- 共识别9 742 773例白内障手术,其中128 254例为手术时正在使用全身皮质类固醇或免疫抑制剂的患者。
- 按葡萄膜炎诊断及全身皮质类固醇或免疫抑制治疗情况分为A、B、C、D四组,采用多因素logistic回归评估眼内炎风险。
主要发现
- 白内障术后60天内急性眼内炎发生率在A、B、C、D组分别为0.058%、0.468%、0.137%、0.964%。
- 眼内炎诊断发生率最高见于有葡萄膜炎诊断的眼;无论有无葡萄膜炎,接受免疫抑制剂或皮质类固醇治疗的患者眼内炎发生率均更高。
- 多因素logistic回归分析显示全身皮质类固醇较全身免疫抑制剂与眼内炎关联更强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the differences in incidence of acute postoperative endophthalmitis after cataract surgery in the setting of uveitis and immunosuppressive therapy using the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). DESIGN: Retrospective cohort study. PARTICIPANTS: Patients undergoing cataract surgery in the United States from 2013 to 2023. METHODS: The IRIS Registry was queried to identify cataract surgeries performed between January 1, 2013, and March 21, 2023. Postoperative endophthalmitis was identified based on endophthalmitis diagnosis codes and vitreous tap and intravitreal antibiotic injection within 60 days after surgery. Cases with a recent noninfectious uveitis diagnosis within 1 year before cataract surgery were also identified. Active use of systemic corticosteroids and immunosuppressives was determined using drug names and the National Library of Medicine Rx Concept Unique identifier. Eyes that underwent cataract surgery were classified into 4 groups: Group A: Eyes with no uveitis in patients with no concurrent systemic corticosteroid or immunosuppressive treatment (general population). Group B: Eyes with recent uveitis in patients with no concurrent systemic corticosteroid or immunosuppressive treatment. Group C: Eyes with no uveitis in patients with concurrent systemic corticosteroid or immunosuppressive treatment. Group D: Eyes with recent uveitis in patients with concurrent systemic corticosteroid or immunosuppressive treatment. Multivariable logistic regression was performed to evaluate the likelihood of endophthalmitis. MAIN OUTCOME MEASURES: Incidence of acute-onset postoperative endophthalmitis in eyes with a uveitis diagnosis and in eyes of patients under systemic corticosteroid and immunosuppressive therapy. RESULTS: A total of 9 742 773 cataract surgeries were identified; of those, 128 254 were in patients on systemic corticosteroids or immunosuppressives at the time of surgery. The incidence of acute postoperative endophthalmitis within 60 days after surgery was 0.058%, 0.468%, 0.137%, and 0.964%, in groups A, B, C, and D, respectively. The highest incidence of endophthalmitis diagnoses was in eyes with uveitis diagnoses; however, among eyes with and without uveitis, endophthalmitis incidence was higher in patients treated with immunosuppressives or corticosteroids. Multivariate logistic regression analysis revealed that systemic corticosteroids were more associated with endophthalmitis compared with systemic immunosuppressives. CONCLUSIONS: Underlying uveitis diagnosis, systemic corticosteroids, and immunosuppressives are associated with an increased likelihood of acute postoperative endophthalmitis after cataract surgery. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Ghoraba HH, Haque ME, Or C, et al. Incidence of Endophthalmitis after Cataract Surgery in the Setting of Uveitis and Immunosuppressive Therapy within the IRIS® Registry. Ophthalmology. 2025. PMID: 40499788. doi:10.1016/j.ophtha.2025.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。